Karpus Management Inc. Trims Stock Holdings in TLGY Acquisition Co. (NASDAQ:TLGY)

Karpus Management Inc. reduced its stake in TLGY Acquisition Co. (NASDAQ:TLGY) by 1.4% during the 1st quarter, Holdings Channel reports. The institutional investor owned 420,050 shares of the company’s stock after selling 6,050 shares during the period. Karpus Management Inc.’s holdings in TLGY Acquisition were worth $4,747,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Wolverine Asset Management LLC raised its holdings in TLGY Acquisition by 59.0% in the 4th quarter. Wolverine Asset Management LLC now owns 480,485 shares of the company’s stock valued at $5,324,000 after buying an additional 178,200 shares during the period. Berkley W R Corp raised its holdings in TLGY Acquisition by 9.6% in the 4th quarter. Berkley W R Corp now owns 280,470 shares of the company’s stock valued at $3,119,000 after buying an additional 24,635 shares during the period. Crystalline Management Inc. purchased a new stake in TLGY Acquisition in the 4th quarter valued at about $1,666,000. Cowen AND Company LLC purchased a new stake in TLGY Acquisition in the 4th quarter valued at about $1,509,000. Finally, Spartan Fund Management Inc. purchased a new stake in TLGY Acquisition in the 4th quarter valued at about $1,386,000. 45.08% of the stock is currently owned by hedge funds and other institutional investors.

TLGY Acquisition Price Performance

TLGY remained flat at $11.46 on Thursday. TLGY Acquisition Co. has a 1 year low of $10.80 and a 1 year high of $11.49. The business’s 50 day moving average price is $11.44 and its 200 day moving average price is $11.33.

About TLGY Acquisition

TLGY Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. It intends to acquire companies in the biopharma or technology enabled business-to-consumer industries worldwide.